Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Dominick J. Angiolillo, MD, PhD, FACC*,*,
Esther Bernardo, BSc, ,
Manel Sabaté, MD, PhD,
Pilar Jimenez-Quevedo, MD,
Marco A. Costa, MD, PhD, FACC*,
Jorge Palazuelos, MD, PhD,
Rosana Hernández-Antolin, MD, PhD,
Raul Moreno, MD,
Javier Escaned, MD, PhD,
Fernando Alfonso, MD, PhD,
Camino Bañuelos, MD,
Luis A. Guzman, MD, FACC*,
Theodore A. Bass, MD, FACC*,
Carlos Macaya, MD, PhD and
Antonio Fernandez-Ortiz, MD, PhD
* Division of Cardiology, University of Florida College of Medicine—Shands Jacksonville, Jacksonville, Florida
Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Interindividual Distribution of Platelet Aggregation
Normal bell-shaped distribution of maximal adenosine diphosphate (ADP) (20 µmol/l)-induced platelet aggregation in the overall diabetic population (n = 173) assessed at study entry (6 to 9 months after initiation of dual antiplatelet therapy).
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Cumulative Event-Free Survival According to Quartile Distribution of Platelet Aggregation
Cumulative event-free survival from cardiovascular events according to quartile (Q) distribution of maximal adenosine diphosphate (20 µmol/l)-induced platelet aggregation.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Cumulative Event-Free Survival According to Optimal ROC-Defined Cutoff Value
Cumulative event-free survival from cardiovascular events according to the optimal receiver-operating characteristic (ROC)-defined cutoff value of 62% maximal adenosine diphosphate (20 µmol/l)-induced platelet aggregation (Aggmax).
|
|
|
